|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 471 Hashimoto's thyroiditis (HT) patients, the significant difference was revealed in anti-thyroid peroxidase antibody (TPOAb) concentration, the cytokeratin-19 (CK-19) expression, the occurrence of the B-Raf proto-oncogene serine/threonine kinase (BRAF) mutations and the rearrangement in transformation (RET)/PTC.
|
31497359 |
2019 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutation could be demonstrated at significantly lower rates in cases of PTC + HT (32.1 vs 60.7%, p < 0.005).
|
30666518 |
2019 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation rate was 93/120 in PTC, 47/64 in PTMC, 3/34 in NG and 2/28 in HT.
|
29541194 |
2018 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, older age and microcalcification are risk factors for BRAF mutation in PTC patients, especially in those without HT.
|
28687736 |
2017 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of the BRAF<sup>V600E</sup> mutation was demonstrated to be significantly associated with extrathyroidal extension (P=0.019), advanced Tumor-Node-Metastasis stage (P=0.007) and the presence of autoimmune thyroiditis (P=0.010).
|
28454296 |
2017 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Negative status of BRAF(V600E) mutation negative was significantly associated with gender (OR = 0.90, 95%CI = 0.83-0.97) and concomitant hashimoto thyroiditis (OR = 0.53, 95%CI = 0.43-0.64).
|
26871894 |
2016 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, Hashimoto's thyroiditis was related to less lymph node metastasis and extrathyroidal extension in PTCs with BRAF(V600E) mutation.
|
26041461 |
2016 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, BRAF mutation was significantly less frequent in conventional PTC patients with CLT.
|
26598713 |
2016 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The pooled analysis indicated that age<45 years (OR = 1.57, 95%CI:1.48-1.66, P < 0.001), male gender (OR = 1.79, 95%CI: 1.69-1.91, P < 0.001), tumor size>10 mm (OR = 2.61, 95%CI:2.27-3.00, P < 0.001), bilaterality (OR = 1.52, 95%CI:1.31-1.77, P < 0.001), multifocality (OR = 1.46, 95%CI: 1.31-1.61, P < 0.001), extracapsular invasion (OR = 2.10, 95%CI:1.81-2.43, P < 0.001), angiolymphatic invasion (OR = 8.02, 95%CI:5.00-12.87, P < 0.001), high histologic risk (OR = 2.62, 95%CI:2.13-3.22, P < 0.001) and BRAF(V600E) mutation (OR:1.78, 95%CI:1.38-2.30, P < 0.001) were significantly associated with CLNM, and upper third location (OR = 0.54, 95%CI:0.43-0.67, P < 0.001) and lymphocytic thyroiditis (OR = 0.64, 95%CI:0.42-0.97, P = 0.034) were decreased risk factors of CLNM.
|
26944586 |
2016 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hashimoto's thyroiditis and BRAF(V600E) status may help to predict clinical outcome of PTC.
|
25213729 |
2016 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Also, recurrence was significantly associated with HT (OR 0.297, CI 0.099-0.890, P = 0.030), lymph node ratio (OR 2.545, CI 1.092-5.931, P = 0.030), and BRAF (V600E) mutation (OR 2.075, CI 1.021-4.217, P = 0.044).
|
25312294 |
2015 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether testing for BRAF mutational status in fine needle aspirates (FNA) is reliable also in the presence of HT lymphocytic infiltration, we assessed the BRAF status by direct sequencing and pyrosequencing in a series of FNAs with and without concomitant HT lymphocytic infiltration.
|
23775008 |
2014 |
|
Hashimoto Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hashimoto's thyroiditis also seemed to play an important role, since benign specimens with Hashimoto's thyroiditis had a 2.2-fold higher B-Raf expression than samples without thyroiditis (1.71 ± 0.63 vs. 0.78 ± 0.13).
|
23263826 |
2013 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation is associated with a more advanced PTC at diagnosis; however, its role in the clinicopathological characteristics of PTC with concurrent HT is unknown.
|
23469895 |
2013 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The BRAF mutation was differentially detected in each histologic subtype of PTC and was strongly correlated with pathologic factors, most strongly with no coexistent chronic lymphocytic thyroiditis, in conventional PTC.
|
23496275 |
2013 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The BRAF mutation was underrepresented among PTCs with accompanying chronic lymphocytic thyroiditis (CLT) compared with PTCs without this feature (12 vs 44%).
|
22457234 |
2012 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Univariate analysis was used to correlate CXCR4 expression with the papillary thyroid carcinoma variant, the degree of neoplastic infiltration, the American Joint Commission on Cancer stage, the presence of lymphocytic thyroiditis and the mutation status of the BRAF gene.
|
21909080 |
2012 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating BRAF point mutations, RAS aberrations, and RET rearrangements are mutually exclusive events in the oncogenesis of papillary thyroid carcinoma, and RET rearrangements have been previously described in dominant nodules of HT.
|
20012784 |
2010 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change.
|
19926583 |
2009 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
|
19014278 |
2009 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Screening for activating BRAF mutations in a series of 83 PTCs identified the most common V600E mutation in 39 cases (histologically, 38 classic PTCs and 1 sclerosing variant PTC) and a complex in-frame mutation involving amino acids V600-S605 in a stage III multicentric follicular variant PTC, occurring in a 50-year-old female patient, who was affected by hypothyroidism in autoimmune thyroiditis and had a family history of PTC and autoimmune thyroiditis.
|
18426810 |
2008 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis and polymerase chain reaction were used to determine activation of the RET/PTC-RAS-BRAF cascade in HT and PTC.
|
17900235 |
2007 |
|
Hashimoto Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that BRAF is a less frequent mechanism of tumorigenesis in a background of CLT and that BRAF mutation is not present in the atypical follicular epithelium of CLT.
|
17308360 |
2006 |
|
Hashimoto Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that the detection of the BRAF mutation in HT can be helpful for prediction of progress to PTC.
|
16143028 |
2005 |